• ZAF Energy Systems

  Participated · Series A · May 2020

  ZAF Energy Systems develops and commercializes next‑generation battery technologies, including nickel‑zinc (NiZn) and a zinc‑air chemistry. Its batteries use sustainable, nontoxic materials, can be safely and easily recycled, and the company says they deliver the highest power and energy density in their class. ZAF targets a wide range of applications such as electric vehicles, commercial trucking, renewables integration, back‑up power, consumer electronics, mobility, recreation vehicles, and aerospace and defense. The company is led by President and CEO Randy Moore and was incorporated in 2011; it is Joplin, Missouri–based and has locations in Montana and Missouri. ZAF is working with three segments of the U.S. Department of Defense on energy storage solutions where its NiZn batteries provide significant performance enhancements. The company recently raised funding to accelerate licensing and joint venture negotiations, drive commercialization and adoption in key markets, and expand manufacturing capacity. ZAF Energy Systems develops and commercializes next-generation rechargeable nickel-zinc (NiZn) and zinc-air batteries using sustainable, non-toxic materials designed for easy recycling. Its NiZn chemistry is described as delivering high power and energy density, with twice the storage capacity and three times the power of conventional lead-acid batteries in a smaller, lighter package. ZAF reports its batteries are performing well in rigorous testing by major commercial trucking, telecommunications, and large-scale data storage customers, and that customers are ready to place orders once manufacturing capacity is available. The company is using investments to hire employees, expand production, and forge strategic partnerships while pursuing licensing and joint-venture arrangements to enable commercially scaled factories globally. A strategic investment from Wirtz Manufacturing is intended to expand production at ZAF’s Joplin facility from hundreds to thousands of batteries per month to rapidly seed the market. ZAF was incorporated in 2011 and has locations in northwestern Montana and southwest Missouri.

• Flowonix

  Led · Equity · Nov 2014

  Flowonix Medical focuses on advanced implantable drug-delivery solutions, centered on its Prometra II Programmable Infusion Pump System. The company said it will use the proceeds to further investment in sales and marketing infrastructure to support the continued commercial ramp of Prometra II and to expand manufacturing capacity. Flowonix received FDA approval to market the Prometra system in 2012 after conducting its first clinical trial in 2007. Founded in 2005 and led by President and CEO Larry Heaton, the company aims to improve care for patients with chronic pain via implantable drug delivery. The recent financing includes both an equity-style investment and venture term debt, reflecting a mix of capital sources. The company is headquartered in Mount Olive, New Jersey. Flowonix Medical Inc. is a medical device company focused on advanced, implantable drug-delivery solutions, centered on the Prometra Programmable Infusion Pump System. Prometra received FDA marketing approval in 2012 after clinical trials, and the company emphasizes the device's accuracy, longevity and safety for chronic pain treatment. Flowonix plans to use new capital to invest in sales and marketing infrastructure, build and mobilize sales and support teams, and pursue new product development. It also intends to broaden the addressable market to include cancer pain patients and those who fail other implantable treatments. Founded in 2005, Flowonix has offices in New Jersey and Massachusetts and holds multiple patents related to its implantable pump technology. Flowonix Medical develops implantable drug-delivery solutions, notably Prometra, an FDA-approved pump that delivers therapeutic drugs into the spine to treat chronic disorders. The company is focused primarily on alleviating chronic pain. Flowonix intends to use new capital to enter the U.S. market and to continue developing its drug delivery technologies. Founded in 2005 and based in Mt. Olive, New Jersey, the company is led by President and CEO Steve Adler. It recently received FDA approval to market Prometra, positioning the company for commercial expansion. The company raised $25M in funding to support these efforts.

No current team members are available.